A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to examine the safety, tolerability, immunogenicity and
pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive
impairment.